The benefits of antiretroviral therapy (ART) in patients living with HIV (PLWH) in
INTRODUCTION
The quantity of human immunodeficiency virus (HIV) RNA in plasma can be measured accurately by plasma viral load testing (Mylonakis et al., 2001) , which is the gold standard practice in resource-rich countries for detecting treatment failure among people receiving ART (World Health Organization, 2014) . It has been recommended by World Health Organization (WHO, 2014) as a preferred tool for diagnosing and confirming the failure of antiretroviral therapy (ART) (World Health Organization, 2013a) and has become the cornerstone of HIV disease management. Viral load (VL) testing facility has been available at the National Public Health *Corresponding author. E-mail: geeta.nphl@gmail.com. The present study was carried out with the objective of finding out the prevalence of viral suppression (VS) and viral failure (VF) in PLWH on ART in Nepal and to assess the effect of VL testing coverage on ART outcomes in patients treated according to the National ART Guidelines (2009) and National consolidated Guideline for Treating and Preventing HIV in Nepal (2014).
MATERIALS AND METHODS
All cases referred to the NPHL for VL testing from the peripheral ART centers during 2009 to 2015 were included in the study. During 2009-2013 (pre scale-up period, PSuP), VL testing was done for ART treatment monitoring as on-request testing for referred (ART treatment failure) cases whereas, from 2014 (scale up period, SuP), testing was done as part of scale up VL testing program after completion of first six months of ART, for treatment monitoring, as recommended in the National consolidated Guideline for Treating and Preventing HIV in Nepal (2014) .
After recording the demographic and treatment history and obtaining informed consent, blood specimens were collected by venepuncture, taking all biosafety precautions. Plasma was separated for laboratory analysis. In the case of patients who could not travel to the NPHL, plasma specimens were collected at the ART centers and received at the NPHL within 6 h of collection. Specimens were transported in ice-box at temperature between 2 to 8°C, along with VL database, as per guideline.
HIV viral load testing was done at the HIV reference laboratory unit of the National Public Health Laboratory (NPHL), Teku, Kathmandu, Nepal. Viral RNA samples were extracted by QIAamp Viral RNA Mini Kit or Roche's High Pure Viral Nucleic Acid Kit and extracted RNA were analyzed in reverse transcription polymerase chain reaction (RT PCR) Corbett Rotor-Gene 6000, COBAS®TaqMan® 48 Analyzer according to procedural steps, shown in Figure 1 . The VL values obtained were recorded, tabulated and analyzed using appropriate statistical methods. Virological failure was defined as a viral load of > 1000 copies of viral ribonucleic acid (RNA) per ml (World Health Organization, 2013a) and a viral load of < 1000 RNA copies per ml was defined as viral suppression (Bennett et al., 2008) .
RESULTS
Total number of patients on antiretroviral therapy (ART) during the study period was 11,922 and the number of samples tested for viral load (VL) during the same period was 8,230, (2474+5756) which comprised samples tested during both (PSuP and SuP) periods (Table 1 ). The year wise scatter of number of patients receiving ART along with VL test coverage during the same period is shown in Table 2 . Table 3 shows the year wise (2009-15) rate of virological failure (VF) and virological suppression (VS). The VF rate (with exception in 2013) showed progressive fall with the declining trend continuing into the SuP. Virological failure (VF) rate during PSuP and SuP periods is shown in Table 4 .
DISCUSSION
A total of 11,922 patients were on ART treatment during the study period in which 8,230 samples were tested for 
Duration of sample collection
Number of samples Pre scale-up (2009-13) 1528 Scale-up (2014-15) 6702 Total: (PSuP+SuP), 8230 (Zhou et al., 2016) . On the other hand, a higher overall rate of VF (41.3%, 36.4 to 46.4) was reported from Gabon, Africa (Liégeois´et al., 2012).
In the Resource-Poor Settings (RPS), like in Nepal, increasing the availability of ART has improved the survival rates and quality of life for HIV/AIDS patients (Ojha et al., 2016) . However, adherence to the WHO guidelines (World Health Organization, 2013b ) is necessary for continued success. The 90-90-90-UNAIDS treatment target to help end the AIDS epidemic (UN:UNAIDS, 2014) has been a source of great zeal and inspiration in this regard. Despite only 48.3% VL test coverage in the last year of the second segment with a mean VF of 10.2 and 89.8% of all those receiving ART had VS which is very encouraging for achieving the target in the near future.
WHO recommended the use of viral load testing as the preferred method of monitoring response to ART and detecting treatment failure (World Health Organization, 2013b . Although in the past, VL monitoring in the RLS was a topic for much debate (Calmy et al., 2007) , VL testing has been increasingly incorporated in the newer national guidelines for HIV management (Stevens and Marshall, 2010 ; Ministry of Health Government of Lesotho, 2014; Policy Brief, 2015) . Results of the present study document that VL monitoring of ART of PLWH in the RLS improves and optimizes HIV Treatment. This further emphasizes the need to refocus the attention from only increasing access to drugs to VL monitoring to provide optimal treatment to PLWH.
Conclusion
VF failure rate dropped from 27 to 10.2% with increasing VL testing coverage during the period of seven years. VL monitoring improves and optimizes ART of people living with HIV (PLWH).
